Boston Scientific Corporation $BSX Shares Acquired by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 562,800 shares of the medical equipment provider’s stock after acquiring an additional 9,800 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Boston Scientific were worth $54,946,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 7.8% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 4,529 shares of the medical equipment provider’s stock valued at $486,000 after purchasing an additional 326 shares during the last quarter. Norden Group LLC purchased a new position in Boston Scientific during the second quarter worth approximately $302,000. McAdam LLC boosted its stake in Boston Scientific by 5.4% during the second quarter. McAdam LLC now owns 2,404 shares of the medical equipment provider’s stock worth $258,000 after buying an additional 123 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in Boston Scientific by 2.9% in the 2nd quarter. Perigon Wealth Management LLC now owns 13,926 shares of the medical equipment provider’s stock valued at $1,496,000 after buying an additional 394 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,095 shares of company stock worth $9,305,450 in the last ninety days. 0.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Truist Financial reduced their price target on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, January 9th. Robert W. Baird increased their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. BTIG Research reaffirmed a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. Finally, Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $123.89.

Boston Scientific Stock Up 1.4%

Shares of NYSE:BSX opened at $92.56 on Friday. The firm has a market capitalization of $137.22 billion, a PE ratio of 49.50, a price-to-earnings-growth ratio of 1.62 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The firm’s 50-day moving average is $95.70 and its two-hundred day moving average is $99.87.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the business posted $0.63 earnings per share. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.